Science and Research

Immune signatures in NSCLC associated pleural effusions and implications for prognosis

BACKGROUND: Pleural effusions (PEs) are frequent in patients with non-small cell lung cancer (NSCLC) and have prognostic implications. Detection of malignant cells in pleural fluid defines metastatic disease. However, PE cytology has limited sensitivity, leaving a substantial number of PEs cytology negative (Cyt-). We assessed the prognostic significance of cytology positive (Cyt+) and negative effusions and compared biochemical, cellular, and cytokine profiles of NSCLC associated PEs. METHODS: In this retrospective analysis of a prospectively collected prospective multicenter cohort study, PEs were collected from patients with confirmed NSCLC between 2021 and 2025. Effusions were classified as Cyt + or Cyt - based on cytopathology. Clinical data, pleural fluid biochemistry, and differential cell counts were recorded. Cytokine concentrations were measured in PE supernatant using a multiplex ELISA panel and correlated with survival. RESULTS: 111 NSCLC patients with PEs were included in this study (51 Cyt + and 60 Cyt - cases). Cyt + effusions were characterized by significantly lower pH and higher lactate, LDH, and protein concentrations. One year survival was not different in both groups. High pleural lymphocyte counts and a lower pleural neutrophil to lymphocyte ratio were associated with mortality. Cytokine profiling revealed significantly lower IL-5 levels in Cyt + effusions, while other cytokines were comparable. Higher Th2 associated cytokine levels (IL-4 and IL-5) correlated with improved survival independent of cytology status. CONCLUSION: NSCLC-associated cytology positive PEs show distinct immunological features. Survival in patients with Cyt + PEs was similar to those with Cyt- effusions. Pleural immune composition, particularly lymphocyte related markers and Th2 cytokines, may provide additional prognostic information beyond cytology alone.

  • Lombardi, M.
  • Gerckens, M.
  • Alkan, G. H.
  • Khmelovska, D.
  • Gaedtke, L.
  • Weiss, N.
  • Mertens, G.
  • Kramer, J.
  • Melzer, T.
  • Leuschner, G.
  • Yildirim, A. O.
  • Kneidinger, N.
  • Behr, J.
  • Stoleriu, G. M.
  • Mummler, C.
  • Kauffmann-Guerrero, D.

Keywords

  • Humans
  • Female
  • Prognosis
  • *Carcinoma, Non-Small-Cell
  • Lung/immunology/mortality/pathology/diagnosis/complications
  • *Lung Neoplasms/immunology/mortality/pathology/diagnosis
  • Male
  • *Pleural Effusion, Malignant/immunology/pathology/mortality
  • Cytokines/metabolism
  • Aged
  • Middle Aged
  • Retrospective Studies
  • Prospective Studies
  • Biomarkers, Tumor
  • Neutrophils/immunology
  • Cytokines
  • Inflammation
  • Lung cancer
  • Neutrophil-to-lymphocyte ratio
  • Pleural effusion
Publication details
DOI: 10.1016/j.lungcan.2026.109563
Journal: Lung Cancer
Pages: 109563 
Work Type: Original
Location: CPC-M
Disease Area: LC
Partner / Member: ASK, HMGU, KUM
Access-Number: 42570502
See publication on PubMed


chevron-down